Skip to main content

Table 1 Characteristics of patients by ALDH2 genotype

From: ALDH2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignancies

 

Total

Rs671(−)

Rs671(+)

p

All

105

 

56

 

49

  

Sex

 Male

89

(85%)

44

(79%)

45

(92%)

0.059

 Female

16

(15%)

12

(21%)

4

(8%)

 

Age (years)

 Median (IQR)

69

 

69

 

69

 

0.835

 40–49

6

(6%)

4

(7%)

2

(4%)

0.970

 50–59

12

(11%)

6

(11%)

6

(12%)

 

 60–69

37

(35%)

20

(36%)

17

(35%)

 

 70–79

46

(44%)

24

(43%)

22

(45%)

 

 80–89

4

(4%)

2

(4%)

2

(4%)

 

Brinkman Index

 < 100

14

(13%)

10

(18%)

4

(8%)

0.330

 < 1000

39

(37%)

19

(34%)

20

(41%)

 

 ≥ 1000

52

(50%)

27

(48%)

25

(51%)

 

Type of ICI (first dose)

 Pembrolizumab

45

(43%)

24

(43%)

21

(43%)

0.658

 Atezolizumab

20

(19%)

9

(16%)

11

(22%)

 

 Nivolumab

40

(38%)

23

(41%)

17

(35%)

 

Tumor histotype

 Squamous cell carcinoma

30

(29%)

19

(34%)

11

(22%)

0.176

 Adenocarcinoma

64

(61%)

31

(55%)

33

(67%)

 

 Pleomorphic carcinoma

5

(5%)

1

(2%)

4

(8%)

 

 Mesothelioma

2

(2%)

2

(4%)

0

(0%)

 

 Othera

4

(4%)

3

(5%)

1

(2%)

 

TNM classification

 Stage III

25

(24%)

15

(27%)

10

(20%)

0.148

 Stage IV

51

(49%)

30

(54%)

21

(43%)

 

 Unknown

29

(28%)

11

(20%)

18

(37%)

 

Treatment line

 First-line

41

(39%)

21

(38%)

20

(41%)

0.840

 Second-line

31

(30%)

16

(29%)

15

(31%)

 

 Third-line and later

33

(31%)

19

(34%)

14

(29%)

 

Chemotherapy with first ICI

 No

99

(94%)

52

(93%)

47

(96%)

0.683

 Yes

6

(6%)

4

(7%)

2

(4%)

 

PD-L1 (+) ratio in cancer tissue

 < 1%

20

(19%)

5

(9%)

15

(31%)

0.012

 < 50%

22

(21%)

13

(23%)

9

(18%)

 

 ≥ 50%

48

(46%)

26

(46%)

22

(45%)

 

 Unassessed

15

(14%)

12

(21%)

3

(6%)

 

EGFR mutation in cancer tissue

  (−)

81

(77%)

38

(68%)

43

(88%)

0.400

  (+)

8

(8%)

5

(9%)

3

(6%)

 

 Unassessed

16

(15%)

13

(23%)

3

(6%)

 

Neutrophil count in peripheral blood

 Geometric mean (GSD) (/μL)

4663

(3134)

4501

(5167)

4854

(4808)

0.456

 < 3500/μL

29

(28%)

19

(34%)

10

(20%)

0.273

 < 5000/μL

37

(35%)

19

(34%)

18

(37%)

 

 ≥ 5000/μL

39

(37%)

18

(32%)

21

(43%)

 

Lymphocyte count in peripheral blood

 Geometric mean (GSD) (/μL)

1240

(752)

1141

(1093)

1362

(1344)

0.056

 < 1000/μL

31

(30%)

19

(34%)

12

(24%)

0.151

 < 1500/μL

39

(37%)

23

(41%)

16

(33%)

 

 ≥ 1500/μL

35

(33%)

14

(25%)

21

(43%)

 
  1. Rs671(−); ALDH2*1/*1, rs671(+); ALDH2*1/*2 or ALDH2*2/*2, ICI Immune checkpoint inhibitor, IQR Interquartile range, PD-L1 Programmed death-ligand 1, EGFR Epidermal growth factor receptor. a includes combined small cell lung carcinoma, adenosquamous carcinoma of the lung, and non-small-cell lung cancer-not otherwise specified. GSD Geometric standard deviation. p Probability value for Chi-squared test, Fisher’s exact test, Wilcoxon rank-sum test, or unpaired t-test